KalVista Reports $49M in EKTERLY Revenue as Pediatric Expansion Nears

Event summary

  • KalVista generated $49.1M in net product revenue from EKTERLY in the eight months ending December 31, 2025.
  • 1,702 patient start forms recorded in the US, representing nearly 20% of the HAE patient population.
  • Phase 3 KONFIDENT-KID trial for pediatric HAE patients aged 2–11 completed enrollment a year ahead of schedule.
  • EKTERLY launched in Japan through partner Kaken Pharmaceutical and listed on the National Health Insurance drug reimbursement price list.

The big picture

KalVista's strong early adoption of EKTERLY in the US and international markets positions it as a leader in HAE treatment. The pending pediatric expansion could further solidify its market position, but the company must navigate increasing commercialization costs and maintain regulatory momentum. The shift to a December fiscal year end also marks a strategic realignment in financial reporting.

What we're watching

Pediatric Market Entry
Whether KalVista can sustain momentum with the anticipated US pediatric filing in Q3 2026 and launch in 2027.
International Expansion
The pace at which EKTERLY gains traction in markets beyond the US, particularly in Japan and Germany.
Commercial Execution
How KalVista manages rising SG&A expenses while scaling EKTERLY's commercial reach globally.